Grants for Independent school districts - Food and Nutrition

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

This funding opportunity supports researchers in developing innovative tools that can speed up drug development and improve regulatory processes, ultimately enhancing public health by facilitating faster access to effective treatments.

The Rhode Island Strategic Prevention Framework (SPF) Partnerships for Success (PFS) program is specifically tailored to address gaps in alcohol and marijuana use prevention among youth and young adults aged 12-18 in certain communities. These communities include Newport, Tiverton, Burrillville, and Exeter-West Greenwich, identified as high-need areas for prevention efforts. The program, administered by the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities & Hospitals (BHDDH), collaborates with local community prevention providers to implement evidence-based programming aimed at reducing underage and problematic use of alcohol and marijuana among middle and high school students. Eligible applicants for funding include: Local government entities Academic institutions Non-profit organizations Other relevant agencies Schools/school districts Applicants are required to implement one or more preapproved evidence-based practices from a provided list. The aim is to ensure that interventions are grounded in proven strategies for effectiveness. Key details of the funding opportunity: Funds Available: $200,000.00 Award Amount: $50,000.00 (minimum and maximum) Number of Awards: 4 Average Award Size: $50,000.00 Matching Required: No Through this targeted initiative, the Rhode Island SPF PFS program seeks to empower local stakeholders and organizations to address substance abuse prevention needs in their communities effectively. By providing funding, training, and technical assistance, BHDDH aims to support the implementation of evidence-based prevention strategies tailored to the unique challenges and needs of each identified community.

This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

This funding opportunity supports innovative research that investigates how aging affects individuals living with HIV, focusing on improving their health outcomes and addressing related challenges.

This funding opportunity supports innovative, interdisciplinary research projects that aim to fill critical knowledge gaps and advance scientific understanding in areas related to kidney, diabetes, and digestive diseases.

This funding opportunity supports students enrolled in dual-degree medical and research training programs, helping them develop into independent physician-scientists through mentored research and clinical training.

This funding opportunity supports clinical trials aimed at developing new therapies for rare neurodegenerative diseases, such as ALS, and is open to a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity supports research initiatives focused on non-communicable diseases related to HIV at institutions in low- and middle-income countries, encouraging innovative projects and collaborations to improve health outcomes for people living with HIV.

This Notice of Funding Opportunity (NOFO) seeks to foster new multi-disciplinary teams to address how HIV Comorbidities and co-infections within the missions of NIDDK and NIAID interact with viral reservoirs, potentially confounding cure strategies aimed at either sustained viral suppression or elimination from the body. These teams will mechanistically interrogate the impact of inflammation, metabolic perturbations, or other pathophysiological processes associated with these comorbidities or co-infections on reservoir dynamics, and/or the interplay of these conditions and co-infections on HIV reservoir biology in ways that are likely to interact with potential cure strategies.

This grant provides funding for early stage investigators to pursue innovative and high-risk research projects involving human participants, without the need for preliminary data.

This initiative recognizes school food authorities that have successfully improved the nutritional quality of school meals and engaged students and families in healthy eating practices across the U.S.

The Connecticut Department of Transportation (CT DOT) is offering the 2024 Active Transportation Microgrant Program to solicit projects aimed at improving active transportation. This grant program aligns with a mission to foster equitable, safe, accessible, and sustainable transportation options, thereby encouraging healthier and more environmentally friendly travel modes. The program's core objective is to make conditions safer for individuals of all ages to engage in walking, biking, and other active forms of transit, contributing to broader community well-being and environmental sustainability. The primary beneficiaries of this program include municipalities, schools, school districts, and nonprofit organizations, all of which are encouraged to apply. The impact goals are centered on enhancing access and conditions for active transportation users across Connecticut. This includes increasing safety for pedestrians and cyclists, promoting the use of non-motorized transport, and supporting educational initiatives that raise awareness about active transportation benefits and safety. The program prioritizes non-infrastructure projects, explicitly excluding design and construction costs. Eligible activities focus on improving access and conditions for active transportation users. This includes providing bicycle helmets, locks, lights, and maintenance training. It also covers the rental or purchase of bicycle fleets, including adaptive bicycles, League Cycling Instructor (LCI) training, and various programs and materials for pedestrian and bicycle safety education, such as safety vests. The emphasis is on practical, immediate interventions that directly support active transportation without requiring extensive infrastructural development. Expected outcomes and measurable results include an increase in the adoption of active transportation methods, a reduction in accidents involving pedestrians and cyclists due to enhanced safety measures, and a rise in community participation in active transportation events and educational programs. The funding limits for individual microgrants range up to $5,000, with an overall grant size between $1,000 and $10,000, indicating a focus on numerous smaller-scale, impactful projects rather than a few large ones. This approach suggests a strategic priority to broadly distribute resources to foster active transportation at a grassroots level across various communities in Connecticut.

The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity objectives.Areas of interest include:Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

The purpose of the funding opportunity is to expand and advance FDA's Office of Minority Health and Health Equity (OMHHE) work with stakeholders and partners for education, outreach, and public awareness activities on potential risks from skin lightening products containing hydroquinone and/or mercury.Applicants will research and propose innovative and community-based strategies and activities that have the potential to strengthen the science base for education and public health awareness on the use of and potential risks from over-the-counter (OTC) skin lightening products.

Not Available

This funding opportunity provides financial support for new researchers from diverse backgrounds to conduct small-scale health-related studies, helping them advance towards independent research careers.

This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P and F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.